How to order if you are a Patient: Thank you for your interest in our testing. Since all our testing must be ordered by a licensed health care practitioner, please have your current healthcare provider contact us so we can set them up with a Vibrant account.

How to order if you are a Provider: If you are a current Vibrant client, please contact or call your local Territory Sales Manager.

If you don’t have an account with Vibrant Wellness, please fill out a Client Application form to get started.

Milk Component

A comprehensive test to detect sensitivity to multiple peptides in cow’s milk dairy

Delayed sensitivities to peptides in dairy can present up to 72 hours after consuming dairy foods. These sensitivities are based on IgG or IgA antibody-driven reactions and can affect both the local intestinal environment with acute symptoms, as well as the extra-intestinal systems from the skin, to the joints, brain, and other internal organs and tissue systems.

Detecting sensitivity to cow’s milk can be difficult due to its ubiquitous presence in the Western diet, symptom overlap with other common conditions, and the often delayed nature of sensitivity symptoms.

Vibrant has developed the Dairy Zoomer to answer the need for a comprehensive peptide-level test to detect with the highest sensitivity and specificity whether an individual is sensitive to any of the multiple peptides found in cow’s milk.

The Dairy Zoomer will also aid healthcare providers in determining if cow’s milk dairy may be at the root of an individual’s symptoms or medical conditions, and guide nutritional interventions based on specific lab results.

Not Available in New York state
Only healthcare providers licensed in their state may order laboratory testing.

*Vibrant Wellness does not participate in, take assignment, or accept any private insurance. We do not provide super bills and cannot assist with claim resolution for laboratory tests or consultations.


  • αS1-casein & αS2-casein
  • β-casein
  • Beta-casomorphin (BCM 7)
  • K-casein


  • α -Lactalbumin
  • ß – Lactoglobulin
  • Serum albumin
  • Lactoferrin


If you have the following symptoms, you may be a good candidate for the Dairy Zoomer:

  • Abdominal pain during or after meals
  • Diarrhea
  • Bloating
  • Colic(in infants)
  • Vomiting
  • Eczema or other rashes
  • Mucous-filled cough
  • Runny nose
  • Eye irritation
  • Recurring ear infections
  • Other food sensitivities and allergies
  • Atopic dermatitis
  • Family history of dairy allergy
  • Advanced age

What is the difference between the Milk Component test and the Dairy Zoomer?

The Vibrant Milk Component test is a screen for allergic reactions or allergic sensitization to cow’s milk peptides and components, which involve IgE antibodies to the measured peptides.

The Vibrant Dairy Zoomer is a test for sensitivity to cow’s milk peptides, which involve IgG and IgA antibodies, and which are not allergies. We recommend running both tests in order to detect the most possible reactions to cow’s milk in all immunoglobulin (Ig) arms of the immune system.

My Milk Component test shows positive antibodies to milk, but I do not experience any symptoms when I consume milk. Is my test wrong?

Many patients have been sensitized to milk, which means an initial exposure has triggered the production of IgE (allergy specific) antibodies to this food. These antibodies can be detected in the blood of sensitized individuals.

However, because of many variables, antibodies do not always correlate with symptoms and not all milk component peptides are associated with anaphylaxis or severe, life-threatening allergies. Because of this, you may have elevated antibodies on the Milk Component allergy panel, but may not be highly allergic yet. Your healthcare provider will aid you in interpretation of results in conjunction with your symptoms and medical history.

Can I run the Milk Component test in pediatrics?

Yes. While Vibrant has not created reference ranges specific to pediatric populations, this test can and should be run in pediatric populations that are at risk for or suspected of having milk allergies or sensitization.


  • Davoodi SH, Shahbazi R, Esmaeili S, et al. Health-Related Aspects of Milk Proteins. Iranian Journal of
  • Pharmaceutical Research: IJPR.2016;15(3):573-591.
  • Pavia, Lampman, Kriz& Engel, Saunders. Isolation of Casein, Lactose, and Albumin from Milk Adapted by R. Minard (Penn State Univ.) from Introduction to Organic Laboratory Techniques: A Microscale Approach, 1990. Revised 3/20/2000
  • Treweek T (2012). Alpha-Casein as a Molecular Chaperone, Milk Protein, In W. L. Hurley (Eds.), Milk Protein (pp. 85-119). Rijeka, Croatia: InTech
  • Wildner G, Diedrichs-Möhring M. Autoimmune uveitis and antigenic mimicry of environmental antigens.
  • Autoimmunity Reviews.2004;3:383-7
  • Chin-Dusting J, Shennan J, Jones E, Williams C, Kingwell B and Dart A. Effect of dietary supplementation with beta-casein A1 or A2 on markers of disease development in individuals at high risk of cardiovascular disease. Br. J. Nutr.2006;95: 136-44.
  • Karjalainen J1, Martin JM, Knip M, Ilonen J, Robinson BH, Savilahti E, Akerblom HK, Dosch HM. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med. 1992;327(5):302-7.
  • Laugesen M, Elliott R. Ischaemic heart disease, Type 1 diabetes, and cow milk A1 beta-casein. N Z Med J.
  • 2003;116(1168): U295
  • Elliott RB, Harris DP, Hill JP, Bibby NJ, Wasmuth HE. Type I (insulin-dependent) diabetes mellitus and cow
  • milk: casein variant consumption. Diabetologia. 1999;42(3):292-6.
  • Birgisdottir BE1, Hill JP, Thorsson AV, Thorsdottir I. Lower consumption of cow milk protein A1 beta-casein at 2 years of age, rather than consumption among 11- to 14-year-old adolescents, may explain the lower incidence of type 1 diabetes in Iceland than in Scandinavia. Ann NutrMetab. 2006;50(3):177-83
  • Adler K, Mueller DB, Achenbach P, et al. Insulin autoantibodies with high affinity to the bovine milk protein alpha casein. Clinical and Experimental Immunology. 2011;164(1):42-49.
  • Jianqin S, Leiming X, Lu X, Yelland GW, Ni J, Clarke A. Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cow’s milk. Nutrition Journal. 2016;15:35.
  • Vacca-Smith A and Bowen W. The effect of milk and kappa casein on streptococcal glucosyltransferase.
  • Caries Res. 1995; 29: 498-506
  • Chia J S J, McRae J L, Kukuljan S et al. A1 beta-casein milk protein and other environmental pre-disposing
  • factors for type 1 diabetes. Nutrition & Diabetes.2017;7: e274
  • Niebuhr DW, Li Y, Cowan DN, Weber NS, Fisher JA, Ford GM, Yolken R. Association between bovine casein antibody and new onset schizophrenia among US military personnel. Schizophr Res. 2011 May;128(1-3):51-5.
  • Severance EG, Dickerson FB, Halling M, Krivogorsky B, Haile L, Yang S, Stallings CR, Origoni AE, Bossis I, Xiao J, Dupont D, Haasnoot W, Yolken RH. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res. 2010 May;118(1-3):240-7 Davoodi, H., Esmaeili, S. and Mortazavian, A.M.. Effects of Milk and Milk Products Consumption on Cancer: A Review. Comprehensive Reviews in Food Science and Food Safety. 2013;12: 249-264.
  • Luhovyy BL1, Akhavan T, Anderson GH. Whey proteins in the regulation of food intake and satiety. J Am Coll
  • Nutr.2007;26(6):704S-12S.
  • Brück W, Graverholt G and Gibson G. A two-stage continuous culture system to study the effect of supplemental α-lactalbumin and glycomacropeptide on mixed cultures of human gut bacteria challenged with enteropathogenic Escherichia coli and Salmonella serotype Typhimurium. J. Appl. Microbiol. 2003;95 : 44-53. Ng T, Lam T, Au T, Ye X and Wan C. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, protease and integrase by bovine milk proteins. Life Sci.2001;69: 2217-23.
  • De Wit J. Nutritional and functional characteristics of whey proteins in food products. J. Dairy Sci. 1998;81:
  • 597-608.
  • Goldfarb M.F. Relation of Time of Introduction of Cow Milk Protein to an Infant and Risk of Type-1
  • Diabetes
  • Mellitus. J, Proteome Res. 2008;7(5):2165-2167
  • Ehn B M, Ekstrand B, Bengtsson U, Ahlstedt S. Modification of lgE Binding during Heat Processing of
  • the Cow’s Milk Allergen a-Lactoglobulin. J. Agric. Food Chem. 2004; 52:1398-140
  • the Cow’s Milk Allergen a-Lactoglobulin. J. Agric. Food Chem. 2004; 52:1398-140
  • Diabetes Care. 1997;20(5):897-901.
  • Huang BX, Kim HY, Dass C. Probing three-dimensional structure of bovine serum albumin
  • by chemical
  • cross-linking and mass spectrometry. J Am Soc Mass Spectrom.2004;15(8):1237-47.
  • Farrell HM Jr, Jimenez-Flores R, Bleck GT, Brown EM, Butler JE, Creamer LK, Hicks CL,
  • Hollar CM, Ng-Kwai-Hang KF, Swaisgood HE. Nomenclature of the proteins of cows’ milk–sixth
  • revision. J Dairy Sci 2004;87(6):1641-74
  • Giansanti F, Panella G, Leboffe L, Antonini G. Lactoferrin from Milk: Nutraceutical and
  • Pharmacological Properties. Donno D, ed. Pharmaceuticals. 2016;9(4):61.
  • Guggenmos J1, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, Linington C. Antibody
  • cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein
  • butyrophilin in multiple sclerosis. J lmmunol. 2004;172(1):661-8.
  • Stefferl A1, Schubart A, Storch2 M, Amini A, Mather I, Lassmann H, Linington C. Butyrophilin, a
  • milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein
  • in experimental autoimmune encephalomyelitis. J lmmunol. 2000;165(5):2859-65.
  • Vojdani, A et al. Antibodies to neuron-specific antigens in children with autism: possible
  • cross-reaction with
  • encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A
  • Journal of
  • Neuroimmunology. 2002;129(1):168 – 177

Recommended Tests to Consider

Wheat Zoomer
Gut Zoomer
Neural Zoomer

Regulatory Statement

Vibrant testing does not demonstrate absolute positive and negative predictive values for any disease state or condition. Its clinical utility has not been fully established. Vibrant validates the accuracy and precision of the testing but not of its clinical or diagnostic value. So these tests are for wellness and informational purpose only. Vibrant is actively doing clinical research on these samples, de-identified from patients under an IRB and will make research publications towards the same as and when the clinical utility is well established. These tests have been laboratory developed and their performance characteristics determined by Vibrant America LLC, a CLIA-certified laboratory performing the test CLIA#:05D2078809. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. The general wellness test intended uses relate to sustaining or offering general improvement to functions associated with a general state of health while making reference to diseases or conditions. Content provided for informational purposes only and should not be construed as medical advice. Content provided to help you make a healthy lifestyle, dietary, and treatment choices in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being. Please consult with your healthcare practitioner for diagnosis and treatment considerations. The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile.